Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.51 |
| ▸ | F7 | P08709 | 3/20 | 0.51 |
| ▸ | F3 | P13726 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icosabutate SCHEMBL2785319 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT | |
| Icosabutate SCHEMBL15996134 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT | |
| Icosabutate SCHEMBL3678942 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT | |
| Icosabutate SCHEMBL298719 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT | |
| Icosabutate SCHEMBL289973 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT | |
| Icosabutate SCHEMBL18334790 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT | |
| Icosabutate SCHEMBL3678946 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT | |
| Icosabutate SCHEMBL15996220 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT | |
| Icosabutate SCHEMBL21585131 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT | |
| Icosabutate SCHEMBL15995662 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427415-B1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | BASF AS (NO) | 2019-03-20 | — | — | EP | claimed |
| US-8735436-B2 | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-05-27 | — | — | US | claimed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | claimed |
| EP-2248798-A1 | Novel lipid compounds | Pronova BioPharma Norge AS (NO) | 2010-11-10 | — | — | EP | claimed |
| US-12599580-B2 | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same | BASF AS (NO) | 2026-04-14 | — | — | US | disclosed |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-10-14 | — | — | US | disclosed |
| EP-3720431-B1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-10-30 | — | — | EP | disclosed |
| US-20240325336-A1 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | NORTHSEA THERAPEUTICS B.V. (NL) | 2024-10-03 | — | — | US | disclosed |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-05-16 | — | — | US | disclosed |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2024-03-12 | — | — | US | disclosed |
| US-20230090432-A1 | COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME | PRONOVA BIOPHARMA NORGE AS (NO) | 2023-03-23 | — | — | US | disclosed |
| US-11351139-B2 | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same | BASF AS (NO) | 2022-06-07 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
| WO-2012059818-A1 | METHODS OF TREATMENT USING LIPID COMPOUNDS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-10 | — | — | WO | disclosed |
| EP-2427415-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | Pronova BioPharma Norge AS (NO) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128401-A9 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-12-08 | — | — | WO | disclosed |
| WO-2010128401-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128401-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-11-11 | — | — | WO | disclosed |
| EP-2248798-A1 | Novel lipid compounds | Pronova BioPharma Norge AS (NO) | 2010-11-10 | — | — | EP | disclosed |
| EP-2248798-A1 | Novel lipid compounds | Pronova BioPharma Norge AS (NO) | 2010-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | CPT1A, NR1H2, NR1H3 | ALDH1A1 154/4885CYP19A1 229/4885F7 2878/4885 |
| US-11351139-B2 | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same | LIPA, SCD5, SBDS | ALDH1A1 1748/4885CYP19A1 835/4885F7 751/4885 |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | ALDH1A1 695/4885CYP19A1 1476/4885F7 1019/4885 |
| US-20240325336-A1 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | ACACA, PC, ACACB | ALDH1A1 525/4885CYP19A1 849/4885F7 4060/4885 |
| US-12599580-B2 | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same | LIPA, LIPC, LIPG | ALDH1A1 3488/4885CYP19A1 1347/4885F7 1015/4885 |
| US-20230090432-A1 | COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME | LIPA, SCD5, SBDS | ALDH1A1 1748/4885CYP19A1 835/4885F7 751/4885 |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H2, NR1H3 | ALDH1A1 154/4885CYP19A1 229/4885F7 2878/4885 |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H3, NR1H2 | ALDH1A1 162/4885CYP19A1 252/4885F7 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.